Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Ebixa (memantine) approved for the treatment of moderate Alzheimer’s disease

14.10.2005


Ebixa extends its indication to become the only drug for moderate and severe Alzheimer’s disease.

The Committee for Medicinal Products for Human Use (CHMP) announced late last night its decision to extend Ebixa’s current indication (moderately severe to severe disease) to include moderate stages of Alzheimer’s disease (AD). Upon implementation of this approval by the European Union Commission, Ebixa will become the first Alzheimer’s drug in Europe to cover the moderate to severe stages of the disease.

In meta-analyses from six international phase III placebo-controlled six-month studies, patients with moderate to severe Alzheimer’s disease (MMSE total score at baseline below 20) showed statistically significant effect in favour of memantine treatment for the cognitive, global, and functional domains. Further analysis showed that twice as many memantine-treated patients showed a statistically significant benefit in preventing marked clinical worsening in all three domains as compared to placebo-treated patients.



“This is an excellent step forward for patients with Alzheimer’s disease”, said Professor Roy Jones, Director of the Research Institute for the Care of the Elderly, Bath, United Kingdom. “Ebixa has shown significant benefits in moderate to severe Alzheimer’s disease and it is at the moderate stage when most patients are currently diagnosed”.

Ebixa has also proven effective in reducing some of the core and most distressing symptoms of AD. Study results have demonstrated that Ebixa-treated patients experienced significant benefits in memory, language and the ability to perform daily activities. Furthermore, Ebixa has proven effective in significantly reducing levels of agitation/aggression, delusions and irritability in patients with AD.

The progression of Alzheimer’s disease is classified according to mild, moderate and severe stages. Moderate to severe disease, when symptoms become more apparent, is estimated to affect 80%(i) of diagnosed Alzheimer’s patients. This significant proportion of Alzheimer’s patients will now have access to this efficacious treatment for Alzheimer’s disease.

Camilla Dormer | alfa
Further information:
http://www.bm.com

More articles from Health and Medicine:

nachricht Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State

nachricht NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Closing the carbon loop

08.12.2016 | Life Sciences

Applicability of dynamic facilitation theory to binary hard disk systems

08.12.2016 | Physics and Astronomy

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D

08.12.2016 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>